Larimar Therapeutics (LRMR) Long-Term Deferred Tax (2022 - 2023)
Larimar Therapeutics' (LRMR) quarterly Long-Term Deferred Tax came in at $142.5 million in Q4 2023, up 8.29% on a YoY basis from $131.6 million in Q4 2022, and up 8.29% quarter-over-quarter from $131.6 million in Q4 2022.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Long-Term Deferred Tax for 2 consecutive years, with $142.5 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Deferred Tax rose 8.29% year-over-year to $142.5 million; the trailing twelve-month figure through Dec 2023 stood at $142.5 million (up 8.29% YoY), and the FY2023 full-year result was $142.5 million, up 8.29% from the prior year.
- Long-Term Deferred Tax improved to $142.5 million in Q4 2023 per LRMR's latest filing, from $131.6 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $142.5 million in Q4 2023 and bottomed at $131.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |